Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab

Publication date: Available online 5 December 2019Source: Journal of Clinical and Experimental HepatologyAuthor(s): Waseem Amjad, Sandy Kotiah, Ankur Gupta, Michael Morris, Li Liu, Paul J. ThuluvathThe use of immunotherapy in transplant recipients is considered a contraindication because of very high risks for graft loss. The graft loss is to be expected because cytotoxic T-lymphocyte–associated protein-4 and programmed death 1 pathways are implicated in graft tolerance. In this case report, we describe a woman with recurrent, disseminated hepatocellular carcinoma who was successfully treated with nivolumab, an immune checkpoint inhibitor.
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research